GILD
Another checkmark in Gilead’s corner
AE Wealth Management LLC just gave Gilead a little more love, boosting its position by 14,470 shares. After the purchase, the fund now owns 58,343 shares worth roughly $7.16 million. Not exactly “all-in, yolo” territory, but definitely the kind of filing that tells you a real-money manager still sees something to like here.
The bigger Gilead cocktail
This isn’t happening in a vacuum. Gilead has also been working through its Arcellx acquisition, which recently cleared the required regulatory approvals — a helpful de-risking step for its cell-therapy and oncology push. So while one investor is adding shares, the company itself is trying to make its next growth chapter look less like a rumor and more like a plan.
But the signal is not all one-way
Wall Street is still doing its usual split-screen routine:
- Morgan Stanley nudged its price target up to $175
- Some firms kept bullish stances intact
- RBC and Zacks, meanwhile, sounded a little less enchanted with near-term drug persistence and EPS trends
- Insiders, including the CEO, have also been selling shares recently
That means you’re looking at a stock with real institutional interest, but not a neat, single-story setup. Think “multiple plotlines,” not “hero’s journey.”
Big picture
For investors, the takeaway is simple: Gilead keeps attracting capital, but the market is still sorting out whether the next leg is powered by execution, M&A, or just good old-fashioned dividend-and-earnings stability. The stock’s not being handed a blank check — but it’s also not being ignored.